|
|
|
| Development and Prospect of Antibody Drugs for SARS-CoV-2 |
WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi( ),SUN Yan-rong() |
| China National Center for Biotechnology Development, Beijing 100039,China |
|
|
|
Abstract With their unique advantages of high affinity and high specificity, antibody drugs have played an increasingly important role in the diagnosis and treatment of malignant tumors, autoimmune diseases, and infectious diseases, becoming the focus of international innovative drug research. Since the outbreak of COVID-19, many research institutions and enterprises at home and abroad are in accelerated development of antibody drugs. In this situation, a systematic analysis of the status and trends of antibody drugs, the research progress of new antibody drugs for SARS-CoV-2, and the opportunities, challenges and suggestions for current antibody drug innovation in China is of great significance to promote the independent innovation of antibody drugs in China.
|
|
Received: 30 March 2020
Published: 02 June 2020
|
|
|
|
Corresponding Authors:
Yi AO,Yan-rong SUN
E-mail: aoyi@cncbd.org.cn;sunry@cncbd.org.cn
|
|
|
| [1] |
Perez H L, Cardarelli P M, Deshpande S , et al. Antibody-drug conjugates: current status and future directions. Drug Discovery Today, 2013, 10.1016/j.drudis.2013.11.004.
doi: 10.1016/j.drudis.2013.11.004
|
|
|
| [2] |
Mould D R, Meibohm B . Drug Development of therapeutic monoclonal antibodies. BioDrugs, 2016,30:275-293.
|
|
|
| [3] |
WHO. Coronavirus disease (COVID-19) outbreak.[2020-03-26]. https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd.
|
|
|
| [4] |
陶维红, 李宗海, 李荣秀 . 我国单克隆抗体药物产业化进展浅谈. 生物产业技术, 2019,02(3月):75-80.
|
|
|
| [4] |
Tao W H, Li Z H, Li R X . Progress of monoclonal antibody drug industrialization in China. Biobusiness, 2019,02(March):75-80.
|
|
|
| [5] |
Kretschmer A, Schwanbeck R, Valerius T , et al. Antibody isotypes for tumor immunotherapy. Transfus Med Hemother, 2017,44(5):320-326.
doi: 10.1159/000479240
|
|
|
| [6] |
Nimmerjahn F, Ravetch J V . Analyzing antibody-fc-receptor interactions. Methods in Molecular Biology, 2008,415:151-162.
|
|
|
| [7] |
陈秀秀, 吴成林, 周丽君 . 人源抗体制备及临床应用研究进展. 中国生物工程杂志, 2019,39(10):90-96.
|
|
|
| [7] |
Chen X X, Wu C L, Zhou L J . Research progress in preparation and clinical application of human antibodies. China Biotechnology, 2019,39(10):90-96.
|
|
|
| [8] |
Emmons C, Hunsicker L G . Muromonab-CD3 (Orthoclone OKT3): The first monoclonal antibody approved for therapeutic use. Lowa Med, 1987,77:78-82.
|
|
|
| [9] |
U.S. Food&Drug Administration Advancing health through innovation: New drug therapy approvals 2019. [2020.03.01]. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2019.
|
|
|
| [10] |
高倩, 江洪, 叶茂 , 等. 全球单克隆抗体药物研发现状及发展趋势[J]. 中国生物工程杂志, 2019,39(3):111-119.
|
|
|
| [10] |
Gao Q, Jiang H, Ye M , et al. Status and development trend of global monoclonal antibody drug. China Biotechnology, 2019,39(3):111-119.
|
|
|
| [11] |
李敏, 吴日伟 . 国内外单抗药物市场概述. 中国生物工程杂志, 2017,37(3):106-114.
|
|
|
| [11] |
Li M, Wu R W . Overview of the monoclonal antibody drug market at home and abroad. China Biotechnology, 2017,37(3):106-114.
|
|
|
| [12] |
中华人民共和国国家卫生健康委员会. 截至3月25日24时新型冠状病毒肺炎疫情最新情况.[2020-03-26]. http://www.nhc.gov.cn/xcs/yqtb/202003/f01fc26a8a7b48debe194bd1277fdba3.shtml.
|
|
|
| [12] |
National Health Commission of the People's Republic of China. The latest situation of COVID-19 (March 25 24:00). [2020-03-26]. http://www.nhc.gov.cn/xcs/yqtb/202003/f01fc26a8a7b48debe194bd1277fdba3.shtml.
|
|
|
| [13] |
Yan R H, Zhang Y Y, Guo Y Y , et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. bioRxiv, doi: 10.1101/2020.02.19.956946.
doi: 10.1101/2020.02.19.956946
|
|
|
| [14] |
Lan J, Ge J W, Yu J F , et al. Crystal structure of the 2019-nCoV spike receptor-binding domin bound with the ACE2 receptor. bioRxiv, doi: 10.1101/2020.02.19.956235.
doi: 10.1101/2020.02.19.956235
|
|
|
| [15] |
Klasse P J, Sattentau Q J . Mechanisms of virus neutralization by antibody. Current Topics in Microbiology and Immunology, 2001,260:87-108.
|
|
|
| [16] |
Ju B, Zhang Q, Ge X Y , et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv, doi: 10.1101/2020.03.21.990770.
doi: 10.1101/2020.03.21.990770
|
|
|
| [17] |
Wang Q H, Zhang Y F, Wu L L , et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell, doi: 10.1016/j.cell.2020.03.045.
doi: 10.1016/j.cell.2020.03.045
|
|
|
| [18] |
Oldfield V, Dhillon S, Plosker G L . Tocilizumab a review of its use in the management of rheumatoid arthritis. Drugs, 2009,69:609-632.
|
|
|
| [19] |
中华人民共和国国家卫生健康委员会. 关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知.[2020-03-04]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
|
|
|
| [19] |
National Health Commission of the People's Republic of China. Notice on issuing diagnosis and treatment plan for COVID-19 (Trial Version 7). [2020-03-04]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
|
|
|
| [20] |
Wang C Y, Li W T, Drabek D , et al. A human monoclonal I antibody blocking SARS-CoV-2 infection. bioRxiv, doi: 10.1101/2020.03.11.987958.
doi: 10.1101/2020.03.11.987958
|
|
|
| [21] |
周丽丽, 郑祝华 . 类风湿性关节炎治疗药——Kevzara. 药学研究, 2017, 36,(7):432-434.
|
|
|
| [21] |
Zhou L L, Zheng Z H . Rheumatoid arthritis drugs——Kevzara. Journal of Pharmaceutical Research, 2017,36:7.
|
|
|
| [22] |
中国临床试验注册中心. 评价依奇珠单抗联合临床常规抗病毒药物治疗新型冠状肺炎(COVID-19)患者的有效性和安全性的随机盲法对照多中心临床试验.[2020-03-10]. http://www.chictr.org.cn/showproj.aspx?proj=50251.
|
|
|
| [22] |
Chinese Clinical Trial Registry. A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19) .[2020-03-10]. http://www.chictr.org.cn/showproj.aspx?proj=50251.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
